Anemia and iron deficiency in Crohn’s disease

References

• Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn’s disease. Aliment Pharmacol Ther. 2006;24(11–12):1507–1523.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103(5):1299–1307.
   PubMed Web of Science ®Google Scholar
• Pizzi LT, Weston CM, Goldfarb NI, et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(1):47–52.
   PubMed Web of Science ®Google Scholar
• Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12(2):123–130.
   PubMed Web of Science ®Google Scholar
• Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2001;7(3):250–255.
   PubMed Web of Science ®Google Scholar
• Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7(11):599–610.
   PubMed Web of Science ®Google Scholar
• Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease - a practical approach. Ann Gastroenterol. 2013;26(2):104–113.
   PubMedGoogle Scholar
• Ormerod TP. Radio-iron (59Fe) studies in acute ulcerative colitis. Scand J Gastroenterol. 1968;3(2):189–192.
   PubMed Web of Science ®Google Scholar
• Befrits R, Wikman O, Blomquist L, et al. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. Scand J Gastroenterol. 2013;48(9):1027–1032.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Staun M, Bhandari S, et al. State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. J Crohn’s Colitis. 2013;7(6):429–440.
   Google Scholar
• Lee TW, Kolber MR, Fedorak RN, et al. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohn’s Colitis. 2012;6(3):267–275.
   Google Scholar
• Comin-Colet J, Enjuanes C, Gonzalez G, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail. 2013;15(10):1164–1172.
   PubMed Web of Science ®Google Scholar
• Enjuanes C, Klip IT, Bruguera J, et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol. 2014;174(2):268–275.
   PubMed Web of Science ®Google Scholar
• Dallman PR. Biochemical basis for the manifestations of iron deficiency. Annu Rev Nutr. 1986;6:13–40.
   PubMed Web of Science ®Google Scholar
• Jacobs A. Non-haematological effects of iron deficiency. Clin Haematol. 1982;11(2):353–364.
   PubMedGoogle Scholar
• Oustamanolakis P, Koutroubakis IE, Kouroumalis EA. Diagnosing anemia in inflammatory bowel disease: beyond the established markers. J Crohn’s Colitis. 2011;5(5):381–391.
   Google Scholar
• Oustamanolakis P, Koutroubakis IE, Messaritakis I, et al. Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease. J Crohn’s Colitis. 2011;5(4):295–300.
   Google Scholar
• Oustamanolakis P, Koutroubakis IE, Messaritakis I, et al. Soluble transferrin receptor-ferritin index in the evaluation of anemia in inflammatory bowel disease: a case-control study. Ann Gastroenterol. 2011;24(2):108–114.
   PubMedGoogle Scholar
• Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis. 2014;20(5):936–945.
   PubMed Web of Science ®Google Scholar
• Miller SD, Cuffari C, Akhuemonkhan E, et al. Prevalence, and treatment in pediatric inflammatory bowel disease in the United States, 2010–2014. Pediatr Gastroenterol Hepatol Nutr. 2019;22(2):152–161.
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, Stewart JS, Booth CC, et al. Folate deficiency in Crohn’s disease: incidence, pathogenesis, and treatment. BMJ. 1968;2(5597):71–75.
   PubMedGoogle Scholar
• Werlin SL, Grand RJ. Severe colitis in children and adolescents: diagnosis. Course, and treatment. Gastroenterology. 1977;73(4 Pt 1):828–832.
   PubMed Web of Science ®Google Scholar
• Rogler G, Vavricka S. Anemia in inflammatory bowel disease: an under-estimated problem? Front Med (Lausanne). 2014;1:58.
   PubMedGoogle Scholar
• Cartwright GE, Lauritsen MA, Humphreys S, et al. The Anemia Associated With Chronic Infection. Science. 1946;103(2664):72–73.
   Web of Science ®Google Scholar
• Mucke V, Mucke MM, Raine T, et al. Diagnosis and treatment of anemia in patients with inflammatory bowel disease. Ann Gastroenterol. 2017;30(1):15–22.
   PubMed Web of Science ®Google Scholar
• Ott C, Liebold A, Takses A, et al. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterol Res Pract. 2012;595970:2012.
   Google Scholar
• Gasche C, Lomer MC, Cavill I, et al. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53(8):1190–1197.
   PubMed Web of Science ®Google Scholar
• Dudkowiak R, Neubauer K, Poniewierka E. Hepcidin and its role in inflammatory bowel disease. Adv Clin Exp Med. 2013;22(4):585–591.
   PubMed Web of Science ®Google Scholar
• Krause A, Neitz S, Magert HJ, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480(2–3):147–150.
   PubMed Web of Science ®Google Scholar
• Park CH, Valore EV, Waring AJ, et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806–7810.
   PubMed Web of Science ®Google Scholar
• Canavesi E, Alfieri C, Pelusi S, et al. HFE protein: iron metabolism as a target for the anemia of chronic kidney disease. World J Nephrol. 2012;1(6):166–176.
   PubMedGoogle Scholar
• Sun CC, Vaja V, Babitt JL, et al. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012;87(4):392–400.
   PubMed Web of Science ®Google Scholar
• Shanmugam NK, Trebicka E, Fu LL, et al. Intestinal inflammation modulates expression of the iron-regulating hormone hepcidin depending on erythropoietic activity and the commensal microbiota. J immunol (Baltimore, Md: 1950). 2014;193(3):1398–1407.
   PubMed Web of Science ®Google Scholar
• Ross SL, Tran L, Winters A, et al. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell Metab. 2012;15(6):905–917.
   PubMed Web of Science ®Google Scholar
• Qiao B, Sugianto P, Fung E, et al. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab. 2012;15(6):918–924.
   PubMed Web of Science ®Google Scholar
• Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434–1443.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–2093.
   PubMed Web of Science ®Google Scholar
• Theurl I, Mattle V, Seifert M, et al. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood. 2006;107(10):4142–4148.
   PubMed Web of Science ®Google Scholar
• Ward DM, Kaplan J. Ferroportin-mediated iron transport: expression and regulation. Biochim Biophys Acta. 2012;1823(9):1426–1433.
   PubMed Web of Science ®Google Scholar
• De Domenico I, Ward DM, Kaplan J. Hepcidin and ferroportin: the new players in iron metabolism. Semin Liver Dis. 2011;31(3):272–279.
   PubMed Web of Science ®Google Scholar
• Oates PS. The role of hepcidin and ferroportin in iron absorption. Histol Histopathol. 2007;22(7):791–804.
   PubMed Web of Science ®Google Scholar
• Battat R, Kopylov U, Szilagyi A, et al. Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management. Inflamm Bowel Dis. 2014;20(6):1120–1128.
   PubMed Web of Science ®Google Scholar
• Yakut M, Ustun Y, Kabacam G, et al. Serum vitamin B12 and folate status in patients with inflammatory bowel diseases. Eur J Intern Med. 2010;21(4):320–323.
   PubMed Web of Science ®Google Scholar
• Bermejo F, Algaba A, Guerra I, et al. Response to letter: folate deficiency in Crohn’s disease. Scand J Gastroenterol. 2014;49(2):255–256.
   PubMed Web of Science ®Google Scholar
• Bermejo F, Algaba A, Guerra I, et al. Should we monitor vitamin B12 and folate levels in Crohn’s disease patients? Scand J Gastroenterol. 2013;48(11):1272–1277.
   PubMed Web of Science ®Google Scholar
• Wish JB. Assessing Iron Status: beyond Serum Ferritin and Transferrin Saturation. Clinical journal of the American Society of Nephrology : CJASN. 2006;1(Supplement 1):S4–S8.
   PubMedGoogle Scholar
• Hanif E, Ayyub M, Anwar M, et al. Evaluation of serum transferrin receptor concentration in diagnosing and differentiating iron deficiency anaemia from anaemia of chronic disorders. J Pak Med Assoc. 2005;55(1):13–16.
   PubMedGoogle Scholar
• Mast AE, Blinder MA, Gronowski AM, et al. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem. 1998;44(1):45–51.
   PubMed Web of Science ®Google Scholar
• Bager P, Befrits R, Wikman O, et al. High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in Scandinavia: a longitudinal 2-year follow-up study. Scand J Gastroenterol. 2013;48(11):1286–1293.
   PubMed Web of Science ®Google Scholar
• Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica. 2010;95(2):199–205.
   PubMed Web of Science ®Google Scholar
• Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohn’s Colitis. 2015;9(3):211–222.
   Google Scholar
• Hansen TM, Hansen NE, Birgens HS, et al. Serum ferritin and the assessment of iron deficiency in rheumatoid arthritis. Scand J Rheumatol. 1983;12(4):353–359.
   PubMed Web of Science ®Google Scholar
• Thomson AB, Brust R, Ali MA, et al. Iron deficiency in inflammatory bowel disease. Diagnostic efficacy of serum ferritin. Am J Digestive Dis. 1978;23(8):705–709.
   PubMedGoogle Scholar
• Guagnozzi D, Severi C, Ialongo PL, et al. Ferritin as a Simple Indicator of Iron Deficiency in Anemic IBD Patients. Inflamm Bowel Dis. 2006;12(2):150–151.
   PubMed Web of Science ®Google Scholar
• Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13(12):1545–1553.
   PubMed Web of Science ®Google Scholar
• Metzgeroth G, Kripp M, Muller N, et al. The soluble transferrin receptor (TfR)-F-Index is not applicable as a test for iron status in patients with chronic lymphocytic leukemia. Clin Chem Lab Med. 2009;47(10):1291–1295.
   PubMed Web of Science ®Google Scholar
• Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta. 2003;329(1–2):9–22.
   PubMed Web of Science ®Google Scholar
• Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89(3):1052–1057.
   PubMed Web of Science ®Google Scholar
• Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor, ferritin and TfR-F index in identification of latent iron deficiency. Eur J Haematol. 1998;60(2):135–137.
   PubMed Web of Science ®Google Scholar
• Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem. 2002;48(7):1066–1076.
   PubMed Web of Science ®Google Scholar
• Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol. 2005;11(1):14–23.
   PubMedGoogle Scholar
• Oustamanolakis P, Koutroubakis IE. Soluble transferrin receptor-ferritin index is the most efficient marker for the diagnosis of iron deficiency anemia in patients with IBD. Inflamm Bowel Dis. 2011;17(12):E158–159.
   PubMed Web of Science ®Google Scholar
• Syed S, Kugathasan S, Kumar A, et al. Use of Reticulocyte Hemoglobin Content in the Assessment of Iron Deficiency in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2017;64(5):713–720.
   PubMed Web of Science ®Google Scholar
• Urrechaga E, Borque L, Escanero JF. Percentage of hypochromic erythrocytes as a potential marker of iron availability. Clin Chem Lab Med. 2011;50(4):685–687.
   PubMed Web of Science ®Google Scholar
• Brugnara C, Laufer MR, Friedman AJ, et al. Reticulocyte hemoglobin content (CHr): early indicator of iron deficiency and response to therapy. Blood. 1994;83(10):3100–3101.
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Okano H, Teramura M, et al. Content of reticulocyte hemoglobin is a reliable tool for determining iron deficiency in dialysis patients. Clin Nephrol. 2003;59(2):115–123.
   PubMed Web of Science ®Google Scholar
• Chuang CL, Liu RS, Wei YH, et al. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol dialysis trans. 2003;18(2):370–377.
   PubMed Web of Science ®Google Scholar
• Mast AE, Blinder MA, Dietzen DJ. Reticulocyte hemoglobin content. Am J Hematol. 2008;83(4):307–310.
   PubMed Web of Science ®Google Scholar
• Ullrich C, Wu A, Armsby C, et al. Screening healthy infants for iron deficiency using reticulocyte hemoglobin content. Jama. 2005;294(8):924–930.
   PubMed Web of Science ®Google Scholar
• Stoffman N, Brugnara C, Woods ER. An algorithm using reticulocyte hemoglobin content (CHr) measurement in screening adolescents for iron deficiency. J Adolesc Health. 2005;36(6):529.
   PubMedGoogle Scholar
• Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol. 2005;18(2):319–332.
   PubMed Web of Science ®Google Scholar
• Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol. 2011;64(4):287–296.
   PubMed Web of Science ®Google Scholar
• Cakal B, Akoz AG, Ustundag Y, et al. Red cell distribution width for assessment of activity of inflammatory bowel disease. Dig Dis Sci. 2009;54(4):842–847.
   PubMed Web of Science ®Google Scholar
• Hetzel D, Strauss W, Bernard K, et al. III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol. 2014;89(6):646–650.
   PubMed Web of Science ®Google Scholar
• Murawska N, Fabisiak A, Fichna J. Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Diseases: pathophysiology, Diagnosis, and Treatment. Inflamm Bowel Dis. 2016;22(5):1198–1208.
   PubMed Web of Science ®Google Scholar
• Goddard AF, James MW, McIntyre AS, et al. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60(10):1309–1316.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108(12):1877–1888.
   PubMed Web of Science ®Google Scholar
• Sonnweber T, Theurl I, Seifert M, et al. Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol dialysis trans. 2011;26(3):977–987.
   PubMed Web of Science ®Google Scholar
• Ishida JH, Marafino BJ, McCulloch CE, et al. Receipt of Intravenous Iron and Clinical Outcomes among Hemodialysis Patients Hospitalized for Infection. Clin J Am Soc Nephrol. 2015;10(10):1799–1805.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Evstatiev R, Kornek G, et al. Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr. 2015;127(23–24):907–919.
   PubMed Web of Science ®Google Scholar
• Lomer MC, Cook WB, Jan-Mohamed HJ, et al. Iron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel disease. Br J Nutr. 2012;107(12):1806–1811.
   PubMed Web of Science ®Google Scholar
• Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn’s disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis. 2006;12(12):1101–1106.
   PubMed Web of Science ®Google Scholar
• Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med. 2008;121(11):943–948.
   PubMed Web of Science ®Google Scholar
• Carrier J, Aghdassi E, Cullen J, et al. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr. 2002;132(10):3146–3150.
   PubMed Web of Science ®Google Scholar
• Carrier J, Aghdassi E, Platt I, et al. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther. 2001;15(12):1989–1999.
   PubMed Web of Science ®Google Scholar
• Erichsen K, Hausken T, Ulvik RJ, et al. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol. 2003;38(5):543–548.
   PubMed Web of Science ®Google Scholar
• Werner T, Wagner SJ, Martinez I, et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn’s disease-like ileitis. Gut. 2011;60(3):325–333.
   PubMed Web of Science ®Google Scholar
• Munoz M, Gomez-Ramirez S, Garcia-Erce JA. Intravenous iron in inflammatory bowel disease. World J Gastroenterol. 2009;15(37):4666–4674.
   PubMed Web of Science ®Google Scholar
• Bodemar G, Kechagias S, Almer S, et al. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol. 2004;39(5):454–458.
   PubMed Web of Science ®Google Scholar
• Gasche C, Dejaco C, Reinisch W, et al. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. Digestion. 1999;60(3):262–267.
   PubMed Web of Science ®Google Scholar
• Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med. 1997;126(10):782–787.
   PubMed Web of Science ®Google Scholar
• Toblli JE, Cao G, Giani JF, et al. Markers of oxidative/nitrosative stress and inflammation in lung tissue of rats exposed to different intravenous iron compounds. Drug Des Devel Ther. 2017;11:2251–2263.
   PubMed Web of Science ®Google Scholar
• Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. Am J Hematol. 2018;93(5):683–690.
   PubMed Web of Science ®Google Scholar
• Gattermann N. The treatment of secondary hemochromatosis. Dtsch Arztebl Int. 2009;106(30):499–504, i.
   PubMedGoogle Scholar
• Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res. 2007;31(Suppl 3):S2–6.
   PubMedGoogle Scholar